To view this email as a web page, click here.

 
AMD Awareness Month
 
Pipeline for dry AMD holds promise
About 85% to 90% of the cases of macular degeneration are the “dry” (atrophic) type. To date, there are no approved pharmacologic treatments for the dry form of AMD, but there are several studies under way.
Learn more
ADVERTISEMENT
 
ICYMI: State of AMD research in 2018
image description here The past year had its share of groundbreaking research in age-related macular degeneration (AMD). Here is a brief overview of what’s been presented or published within the past 12 months.

Learn more
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.